Michel Detheux - Mar 11, 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role: Chief Executive Officer
Signature: /s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol: ITOS
Transactions as of: Mar 11, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/14/2022, 07:59 PM
Previous filing: Feb 24, 2022
Next filing: Mar 22, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITOS	Common Stock	Award	$0	+10K	+28.82%	$0.00	44.7K	Mar 11, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITOS	Stock Option (Right to Buy)	Award	$0	+353K		$0.00	353K	Mar 11, 2022	Common Stock	353K	$36.21	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying such RSUs will vest on the first anniversary of the grant date, and the remaining shares subject to the RSUs will vest on a quarterly basis thereafter in equal installments over the following twelve (12) quarters, subject to the Reporting Person's continued service to the Issuer.
F2	This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer.

Content

The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying such RSUs will vest on the first anniversary of the grant date, and the remaining shares subject to the RSUs will vest on a quarterly basis thereafter in equal installments over the following twelve (12) quarters, subject to the Reporting Person's continued service to the Issuer.

This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer.